Jersey: Ogier Advises On $300 Million Fund Targeting European Life Sciences
Last Updated: 6 July 2017

Ogier has advised long-standing life sciences-focused investment firm client Medicxi on the launch of a new $300 million growth fund targeting late stage companies in European life sciences.

Key investors in the new fund include the European Investment Fund, an EU agency that supports SMEs.

An Ogier team led by Niamh Lalor, the head of the firm's Jersey Investment Funds team, provided Jersey legal advice on the fund, which was established as a Jersey expert fund.

Medicxi, based in London, Geneva and Jersey, says that the new fund (named Medicxi Growth I) will fill a clear late-stage funding gap in Europe by offering financial support to life sciences entrepreneurs.

Niamh said: "We are delighted to have worked with Medicxi once again, having advised on the establishment of Medicxi last year. With the strategic partnerships established by the launch of the MG1 fund, Medicxi is making a clear and ambitious statement of confidence in the European life sciences industry."

The Ogier team, which included associate Tara Kapur, worked with lead counsel Travers Smith on the launch.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Press Releases from this Firm
Recent Content from this Firm
By Martyn Baudains
By Michael Killourhy
By Michael Killourhy
By Daniel Richards
By Marc Lenaers
By Fraser Allister, Anthony Partridge
By Alice Bricogne
By James Campbell, Katherine Neal
By Bertrand Geradin
By Niamh Lalor, Craig Cordle, Sophie Reguengo, Gabrielle Saul
Font Size: